|
Crusade is a company committed to
the development and application of its herpes simplex virus technology
platform for human disease.
The company represents the accumulated knowledge
of over 30 years of research, development and innovation in the
field of virus technology.
Our key therapeutic and commercial
areas of interest are:
- Herpes simplex virus (HSV)
oncolytic therapy for cancer by harnessing the natural ability
of viruses to destroy cells.
- HSV enhanced oncolytics which
combine the killing potential of virus with routine treatments
like chemo and radiotherapy to outwit the intransigence of certain
incurable cancers.
- HSV therapeutic delivery platform
which allows the virus to be used as the prime carrier to
safely introduce therapeutic agents (visit hsv-vectors.com).
- Non virus based small molecule
and protein derivatives with applications in cancer and non
cancerous conditions eg stroke.
Following dialogue with cancer clinicians,
our chosen human disease for first clinical application of the
technology is glioma, a particularly aggressive form of brain
tumour where we believe our virotherapy can make an impact. |
